Neither the neratinib/dasatinib combination nor the gefitinib/bosutinib combination displayed significant synergy, indicating that blocking EGFR, Src or both achieved largely the same effect on HCC-827 viability, further demonstrating that Src and EGFR are not independent drivers in HCC-827. This evidence concerns the gene SRC and hepatocellular carcinoma.